Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Early OCT Changes After Lucentis in Neovascular AMD
NCT01669447Phase 4Unknown
- Start
- Sep 2012
- Primary completion
- Nov 2012
- Modality
- Antibody Fragments, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 4 trial of ranibizumab in age-related macular degeneration (AMD). Status: unknown.
02
Drugs
ranibizumab
03
Conditions
age-related macular degeneration (AMD)
Beyond the preview
Go deeper on NCT01669447.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01669447.